Create

Sign in to ReadmeX

or

How we handle your data: Privacy Policy

ReadmeX

Your AI reading companion

What would you like to catch up on?

Pick a briefing, or ask your own question.

Your community and people briefings stay personal to you.

Vertex Pharmaceuticals

AI overview

Sign in and the AI will write an overview from our coverage.

Headlines · 2

  1. Drug executives challenge near-term AI disease-cure predictions

    TechNews, citing The Wall Street Journal, reports that Anthropic CEO Dario Amodei has predicted AI could cure most human diseases within ten years, but executives from Vertex Pharmaceuticals, AstraZeneca, and Regeneron dispute near-term claims of sweeping cures or sharply shortened drug-development timelines. Vertex CEO Jeff Leiden said about 50 AI companies failed to produce a usable drug when given data on thousands of its compounds, while McKinsey senior partner Alex Devereson said current models cannot reliably predict the safety problems behind roughly one-quarter of mid-to-late-stage development failures. McKinsey data cited by TechNews shows $8.4 billion in global venture-capital and private-equity investment in AI drug development during 2025, although only a small number of AI-native biotechnology companies reached late-stage trials and none of their drugs had FDA approval.

    科技新报 · 🔥 0
  2. Amodei’s AI disease-cure forecast draws medical scrutiny

    Anthropic CEO Dario Amodei said in an IPO roadshow video that properly applied AI could make cancer, Alzheimer’s disease, heart disease and mental illness history in under a decade. Medical and pharmaceutical experts cited by IT之家 and 36氪 questioned the timeline, noting that laboratory testing, animal studies, clinical trials and regulatory approval remain necessary; as of 2026, no AI-designed drug had reached broad clinical use.

    虎嗅 AI · 🔥 0

Experience and discussion from the community

Share my Vertex Pharmaceuticals experienceAsk about Vertex Pharmaceuticals

Nobody has shared their experience with Vertex Pharmaceuticals yet.